T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Natural Resources
CNQ
|
+$670M |
| 2 |
Martin Marietta Materials
MLM
|
+$496M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$462M |
| 4 |
Lam Research
LRCX
|
+$420M |
| 5 |
argenx
ARGX
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ingersoll Rand
IR
|
+$1.12B |
| 2 |
Xcel Energy
XEL
|
+$944M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$858M |
| 4 |
KKR & Co
KKR
|
+$572M |
| 5 |
Analog Devices
ADI
|
+$515M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.7% |
| 2 | Healthcare | 19.81% |
| 3 | Industrials | 12.92% |
| 4 | Consumer Discretionary | 11.85% |
| 5 | Financials | 11.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Healthcare Realty
HR
$6.6B
| $55.1M | 0.03% |
3,894,739
+1,531,683
| +65% | +$23.1M |
|
377
MoonLake Immunotherapeutics
MLTX
$1.4B
| $55M | 0.03% |
1,095,101
-125,501
| -10% | -$6.81M |
|
|
SF
378
Stifel
SF
$12.9B
| $54.9M | 0.03% |
+1,053,863
| New | +$51.9M |
|
379
Atmos Energy
ATO
$28.7B
| $54.6M | 0.03% |
459,533
+136,208
| +42% | +$15.6M |
|
380
Middlesex Water
MSEX
$1.11B
| $54.5M | 0.03% |
1,038,211
+628,605
| +153% | +$34.8M |
|
|
PCH
381
DELISTED
PotlatchDeltic
PCH
| $54M | 0.03% |
1,147,870
-539,028
| -32% | -$24.8M |
|
|
PRA
382
DELISTED
ProAssurance
PRA
| $53.6M | 0.03% |
4,166,961
+10,001
| +0.2% | +$129K |
|
383
Agilysys
AGYS
$3.2B
| $53.5M | 0.03% |
635,189
-221,707
| -26% | -$17.9M |
|
|
SAFE
384
Safehold
SAFE
$1.09B
| $53.2M | 0.03% |
2,584,096
+119,371
| +5% | +$2.48M |
|
|
CHUY
385
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
| $52.5M | 0.03% |
1,557,100
-371,718
| -19% | -$12.7M |
|
386
Vishay Intertechnology
VSH
$5.12B
| $52.5M | 0.03% |
2,314,433
+630,040
| +37% | +$14M |
|
387
Interparfums
IPAR
$3.71B
| $52.5M | 0.03% |
+373,314
| New | +$52.9M |
|
388
Pennant Group
PNTG
$1.35B
| $52.4M | 0.03% |
2,670,083
-48,803
| -2% | -$822K |
|
389
Zentalis Pharmaceuticals
ZNTL
$299M
| $52.3M | 0.03% |
3,319,086
+977,303
| +42% | +$13.4M |
|
390
Structure Therapeutics
GPCR
$3.89B
| $52.1M | 0.03% |
1,216,303
-95,892
| -7% | -$4.04M |
|
|
VBTX
391
DELISTED
Veritex Holdings
VBTX
| $51.8M | 0.03% |
2,528,416
-2,121,502
| -46% | -$43.9M |
|
|
HLVX
392
DELISTED
HilleVax
HLVX
| $50.9M | 0.03% |
3,061,704
+1,607,914
| +111% | +$25.7M |
|
393
Encore Capital Group
ECPG
$2.14B
| $50.7M | 0.03% |
1,112,595
+28,611
| +3% | +$1.41M |
|
394
FIGS
FIGS
$2.45B
| $50.5M | 0.03% |
10,131,861
+614,408
| +6% | +$3.53M |
|
395
Arrowhead Research
ARWR
$12.1B
| $50.3M | 0.03% |
+1,758,883
| New | +$56.3M |
|
396
nCino
NCNO
$2.24B
| $50.1M | 0.03% |
1,340,384
+71,469
| +6% | +$2.25M |
|
397
Carpenter Technology
CRS
$26.6B
| $49.4M | 0.03% |
691,508
-93,269
| -12% | -$6.1M |
|
398
Neumora Therapeutics
NMRA
$322M
| $49.3M | 0.03% |
+3,584,004
| New | +$57.9M |
|
399
RenaissanceRe
RNR
$13.3B
| $49.2M | 0.03% |
209,221
+70,242
| +51% | +$15.6M |
|
400
Savers
SVV
$1.67B
| $49.1M | 0.03% |
2,545,198
+205,351
| +9% | +$3.83M |
|
Similar funds
T. Rowe Price Investment Management's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Investment Management held 669 positions worth $163B, up 6.3% from $154B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
T. Rowe Price Investment Management's Q1 2024 filing shows 73 new, 322 increased, 222 reduced and 49 closed positions. Its largest new stake was NiSource: 11,684,654 shares worth $323M. The largest sale was Ingersoll Rand, an estimated $1.12B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Industrials.
- T. Rowe Price Investment Management's largest Q1 2024 buy was NiSource: 11,684,654 shares worth $323M.
- T. Rowe Price Investment Management added most to Canadian Natural Resources in Q1 2024, an estimated $670M increase.
- T. Rowe Price Investment Management's biggest Q1 2024 reduction was Ingersoll Rand, cutting an estimated $1.12B.
- T. Rowe Price Investment Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $858M.
- T. Rowe Price Investment Management's ten largest holdings make up 15% of its $163B portfolio in Q1 2024.
- T. Rowe Price Investment Management opened 73 new positions and closed 49 in Q1 2024.
- T. Rowe Price Investment Management's portfolio value rose 6.3% quarter-over-quarter to $163B.
Based on T. Rowe Price Investment Management's 13F filing for Q1 2024, filed 15 May 2024.